CD276 Antikörper (Biotin)

Produktnummer ABIN7077083

Produktdetails anti-CD276 Antikörper (Biotin)

Target: CD276

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CD276 Antikörper ist konjugiert mit Biotin

Applikation: Flow Cytometry (FACS)

Produktmerkmale: The clone DCN.70, a mouse monoclonal antibody selectively binds with a k type I membrane protein commonly known as CD276, a member of B7-H3 immunoregulatory family. It is not expressed by lymphocytes or granulocytes but weakly expressed on resting monocytes. Increased expression is observed on monocytes derived dendritic cells as well as in a variety of cancer types, including breast, pancreatic, and ovarian cancer. CD276 expression has been correlated with poor survival in ovarian cancer subjects. CD276 blockade, especially when combined with an anti-PD-1 blockade, is a promising strategy for the treatment of B7-H3-expressing NSCLCs that arerefractory to anti-PD-1 therapy, making CD276 a promising clinical molecular target.

Aufreinigung: Purified

Reinheit: >95 %

Güteklasse: GMP Grade

Immunogen: Human Dendritic Cells

Klon: DCN-70

Isotyp: IgG1 kappa

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: PBS pH 7.2, 0.09 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Details zu CD276

Target: CD276

Andere Bezeichnung: CD276 (CD276 Produkte)

Synonyme: sc:d0645 antikoerper, zgc:158279 antikoerper, 6030411F23Rik antikoerper, AU016588 antikoerper, B7RP-2 antikoerper, B7h3 antikoerper, B7H3 antikoerper, 4Ig-B7-H3 antikoerper, B7-H3 antikoerper, CD276 molecule antikoerper, CD276 molecule S homeolog antikoerper, CD276 antigen antikoerper, Cd276 molecule antikoerper, CD276 antikoerper, cd276.S antikoerper, cd276 antikoerper, Cd276 antikoerper

Hintergrund: The clone DCN.70, a mouse monoclonal antibody selectively binds with a k type I membrane protein commonly known as CD276, a member of B7-H3 immunoregulatory family. It is not expressed by lymphocytes or granulocytes but weakly expressed on resting monocytes. Increased expression is observed on monocytes derived dendritic cells as well as in a variety of cancer types, including breast, pancreatic, and ovarian cancer. CD276 expression has been correlated with poor survival in ovarian cancer subjects. CD276 blockade, especially when combined with an anti-PD-1 blockade, is a promising strategy for the treatment of B7-H3-expressing NSCLCs that arerefractory to anti-PD-1 therapy, making CD276 a promising clinical molecular target.

Gen-ID: 80381

UniProt: Q5ZPR3

Pathways: Cancer Immune Checkpoints